Neumora Therapeutics, Inc.
NMRA · XNASCIK 1885522fmd_1H02YV34X97HKQCQP7G97N5VFVManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2022 to Jun 30, 2026, 18 periods
FinancialMD model-based estimates
Our own baseline estimates, computed from this company's SEC filings and its own published guidance by a fixed, published method. They are not consensus and not analyst or Street estimates. Information only, not investment advice.
Consensus estimates, analyst ratings and price targets
Street consensus, analyst ratings and price targets are licensed data. FinancialMD does not carry them, and the API answers not_covered for them rather than a number it cannot prove. The model-based estimates above are FinancialMD's own and are not a substitute for them.
GET /v1/company/estimates/consensus, GET /v1/company/analyst_ratings: not_covered
What is served instead: Segments · Earnings releases (8-K)